ArticleScientific reports2017
Development of novel monoclonal antibodies against starch and ulvan - implications for antibody production against polysaccharides with limited immunogenicity.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Starch dynamics as an important factor in early stages of somatic embryogenesis - a review.Frontiers in plant science · 2026Review
- Click & sea: using bioorthogonal click chemistry to visualize seaweed cell walls.Annals of botany · 2025Article
- An Exopolysaccharide from the CyanobacteriumACS omega · 2024Review
- Antibody Isolation in C. neoformans.Methods in molecular biology (Clifton, N.J.) · 2024Article
- The extracellular matrix of green algae.Plant physiology · 2023Review
- Review
- Current and future advances in fluorescence-based visualization of plant cell wall components and cell wall biosynthetic machineries.Biotechnology for biofuels · 2021Review
- Unraveling the sugar code: the role of microbial extracellular glycans in plant-microbe interactions.Journal of experimental botany · 2021Review
- Antibody- Based Immunotherapy Combined With Antimycotic Drug TMP- SMX to Treat Infection WithFrontiers in immunology · 2021Article
- Cloning, Expression, and Characterization of a New PL25 Family Ulvan Lyase from Marine BacteriumMarine drugs · 2019Article
- Distribution of arabinogalactan proteins and pectins in the cells of apple (Malus × domestica) fruit during post-harvest storage.Annals of botany · 2019Article
- Report on the Current Inventory of the Toolbox for Plant Cell Wall Analysis: Proteinaceous and Small Molecular Probes.Frontiers in plant science · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibodies (mAbs) are widely used and powerful research tools, but the generation of mAbs against glycan epitopes is generally more problematic than against proteins. This is especially significant for research on polysaccharide-rich land plants and algae (Viridiplantae). Most antibody production is based on using single antigens, however, there are significant gaps in the current repertoire of mAbs against some glycan targets with low immunogenicity. We approached mAb production in a different way and immunised with a complex mixture of polysaccharides. The multiplexed screening capability of carbohydrate microarrays was then exploited to deconvolute the specificities of individual mAbs. Using this strategy, we generated a set of novel mAbs, including one against starch (INCh1) and one against ulvan (INCh2). These polysaccharides are important storage and structural polymers respectively, but both are generally considered as having limited immunogenicity. INCh1 and INCh2 therefore represent important new molecular probes for Viridiplantae research. Moreover, since the α-(1-4)-glucan epitope recognised by INCh1 is also a component of glycogen, this mAb can also be used in mammalian systems. We describe the detailed characterisation of INCh1 and INCh2, and discuss the potential of a non-directed mass-screening approach for mAb production against some glycan targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.